Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The ERK/MAP kinase cascade is frequently dysregulated in cancer, driven by mutations in RAS and Raf.
• Constitutive activation of MEK and ERK signaling contributes to oncogenesis.
• MEK inhibitors offer a therapeutic strategy for cancers with upregulated MAPK signaling.

Purpose of the Study:

• To discover an optimized diphenylamine-based MEK inhibitor with improved metabolic and safety profiles compared to PD-0325901.
• To identify a novel development candidate for targeting aberrant ERK/MAPK signaling in cancer.

Main Methods:

• Structure-guided drug design was employed to identify novel MEK inhibitors.
• Preclinical evaluation of the identified compound (XL518) in vitro and in vivo.
• Assessment of metabolic and safety profiles.

Main Results:

• Discovery of XL518 (GDC-0973), a potent MEK inhibitor.
• XL518 demonstrated robust in vitro and in vivo anti-cancer potency and efficacy.
• The compound exhibited a sustained duration of action in preclinical models.

Conclusions:

• XL518 represents a promising development candidate for cancer therapy.
• The drug candidate exhibits favorable preclinical efficacy and a potentially improved safety profile.
• XL518 is currently undergoing early-stage clinical trials for cancer treatment.